A venture capital firm in Taipei, Taiwan invests in several sectors including biotechnology, semiconductors, commerce, materials, and software. The firm will invest in companies in Series A and B in Taiwan, Japan, and the U.S. Typical check size ranges from $1-3M USD for early-stage deals. The firm also has an angel fund for Seed stage companies with typical check sizes ranging from $100-3000k USD. Currently, 70% of the firm’s portfolio companies are in Taiwan or Taiwanese-related and 30% are in the U.S. or Japan. The firm has an extended network in the U.S., especially from the Silicon Valley and Boston as most of the founding partners are from Stanford University. If the firm is investing in a Taiwanese company, they tend to lead investments, but for overseas investments, the firm will mostly act as a co-investor.
The firm focuses on biomaterials, medical devices and digital health at in-development or clinical stages. The firm does not invest in pharma or drug development. In terms of medical devices, the firm likes to look at surgery-related devices and for digital health, the firm like to look at software for long-term care. Though, firm is open to all indications and can look at orphan diseases depending on the technology.
The firm focuses on companies that can finalize assets by maximum of 9 years due to the limited fund. The firm may take an observer seat on a case-by-case basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Taiwan VC Invests in Biomaterials, Medical Device, and Digital Health Companies, Open to Cross-Border Investment Opportunities
3 AugHot Investor Mandate: Multi-Family Office Fund Seeks New Opportunities in Medtech and Lab Equipment, Focusing on the Western US
3 AugA multi-family venture fund is an active investor in the medical device sector, and is interested in opportunities in the western United States. Initial investments are typically about $150,000 with the potential for follow-on investments totaling $1 million and may be structured as equity or as debt. The firm offers support and expertise to portfolio companies but does not seek a board seat.
The firm is interested in medical technology and lab equipment, including electro-mechanical medical devices, active implantable devices, and surgical instruments. The firm invests only in companies that have already developed a prototype of their product, filed a patent application and have animal data.
The firm seeks to invest in strong management teams with prior experience in the medical device industry. The firm prefers to make investments with the potential to exit within 3-4 years.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Family Office-Backed VC Firm Invests in Healthcare Technologies, With Strong Interest in Mental & Behavioral Health
3 AugA venture capital investment firm based in the US that is supported by a family office who has invested in healthcare operating companies and real estate for over 30 years, seeks to invest in opportunities that align with their strategic interests. Investments in healthcare have included skilled nursing facilities, rehabilitation therapy, institutional pharmacy, hospice, mental health tech, healthcare tech, and home health. The firm looks to work with early stage companies where they can leverage their operating platform. As a private investor, the firm has a very flexible horizon and mandate – investment size can greatly vary on a deal-by-deal basis. The firm has about 20 companies in their its portfolio, and invests all across the USA.
The firm has a robust portfolio that ranges from healthcare to technology to consumer products. While the firm has a broad interest in healthcare, the firm is most interested in technologies that can leverage the firm’s operating platform and resources. The firm’s portfolio companies include workforce transformation, nurse staffing, medical billing, and Fintech that is focused on the healthcare sector, medical billing, and more. The firm also has a strong interest in technologies dedicated to mental & behavioral health. The firm is opportunistic in terms of stage of development. The firm does not consider therapeutics opportunities.
The firm seeks to partner with smart, thoughtful founders with a true commitment in their ideas. The firm is a hands-on investor and seeks to have an active role in their portfolio companies. As mentioned above, the firm is able to leverage its resources to support pilots and enable companies to test new ideas. The firm can also support companies in enhancing their business models, implementing scale through partnerships, and share their own experiences in developing world-class brands.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Large Manufacturer Actively Seeks Strategic Partnerships With Therapeutics Companies, Including Platform Technologies in CVD, Metabolic Disease, and More
3 AugA firm that is a division of a Japan-based manufacturer of various goods including pharmaceuticals, chemicals, etc. – one of the largest privately held companies in Japan – is actively looking for global partnering opportunities that complement the firm’s current research pipeline. Types of partnerships can include in-licensing, co-development, co-commercialization, and potentially more. Though the firm is capable of making investments and may expand upon their methods of partnering with early-stage companies, the firm does not currently have a dedicated venture capital fund.
The firm is primarily interested in therapeutics that complement the firm’s current research pipeline which includes assets in cardiovascular disease, metabolic disease, peripheral arterial disease, and pain management. The firm is interested in novel compounds that they can develop through proof of concept, and is generally stage agnostic. While the firm has historically focused on small molecules, the firm has a growing interest in antibodies and cell therapies. In addition, the firm is strongly interested in platform technologies.
The firm does not have specific company or management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Confirmed Attendees for RESI Boston September. Join them with the Early Bird Rate.
27 JulBy Antoinette Lowre, Manager of Business Development, LSN
RESI Boston September will continue with our hybrid format of 1-day in person at the Boston Park Plaza, followed by 2-days of virtual partnering. Monday, September 18 will feature our Investor Panels (check them out here), along with entrepreneur workshops led by industry expert service providers, and our popular Innovator’s Pitch Challenge (IPC) sessions. All alongside one-on-one partnering meetings from 8am-5pm.
We’re expecting over 300 more investors and strategic partners interested in partnering with early-stage life science companies to join us. Below are the confirmed investor attendees who will be at RESI Boston, September 18-20.
Click Here to See More Investors
In addition to the 300+ investors, we are anticipating 300+ startups looking to raise capital and find providers for services they may need.
SAVE $300 on your registration with the Early Bird Rate, ending tomorrow Friday, July 28th. Register now to join the RESI community this fall! The registration options are as followed:
| Standard 3-day (Sept. 18-20) |
Virtual 2-day (Sept. 19-20) |
|
| STARTUP | $1,695 |
$995 |
| Add the Premier Package* to view the full investor profiles, including contact information. | ||
| SERVICE PROVIDER | $2,195 |
$1,295 |
| EXHIBITOR | $4,390Â |
|
Mastering the Art of Partnering: A Roadmap for Startup Success
27 JulBy Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
In the competitive entrepreneurship landscape, startups often need help distinguishing themselves from the competition; they are in a race to stand out amongst the sea of meeting requests the partners receive. Investors and licensing partners continuously lament the need for startups to develop concise, cogent, and compelling messaging that nets out their value proposition and sheds some light on the team and technology.
The problem lies in the cookie-cutter, problem-solution, market-oriented pitch decks that often fail to convey a strong personal narrative and compelling story. A startup must realize it is essentially a numbers game when they embark on a global partnering initiative. They must engage in dialogue with hundreds of potential partners to find the few that will participate in the round. To start the dialogue, you need to secure a constant flow of meetings with partners who fit your stage of development and product. Therein lies the rub, how does a startup generate a pipeline of meetings with the right players?
Crafting a Compelling Story
Startup founders must recognize that potential investors and licensing partners invest in people before they invest in products or services. Startups must recognize the immense importance of weaving a compelling story that captivates the hearts and minds of potential partners. They should build a strong personal narrative highlighting their passion and vision. This narrative should highlight the founder’s journey, the team’s expertise, and the milestones achieved, backed by validated data. A strong personal narrative resonates with investors and partners, setting the foundation for a meaningful relationship.
Knowing Your Target Audience
In the dynamic world of entrepreneurship, understanding the target audience is key to crafting an effective brand message. Entrepreneurs must identify the ten categories of investors and licensing partners that align with their stage of development and product. Tailoring the pitch and messaging to cater to potential partners’ specific needs and interests significantly increases the chances of securing valuable meetings and partnerships. A concise tagline and compelling elevator pitch enable investors to assess the startup’s value proposition swiftly, paving the way for further engagement.
Making it Easy to Say Yes
A key principle of business development is making it easy for potential partners to say yes to a meeting. Startups should proactively present the “value add” of their founder, team, and technology. Anticipating and addressing potential partner needs and concerns demonstrates professionalism and builds trust. By providing researched, relevant information, startups improve their chances of moving forward in the partnering process.
Embrace the Global Arena
Founders must recognize that staying in their geographic regions limits the number of opportunities, thus hindering the number of partners to engage with. Breaking free from geographic limitations opens the startup to wider opportunities. Expanding globally requires a strategic game plan and sufficient resources to execute a global campaign and roadshow. Adopting and understanding rudimentary sales and marketing tactics, such as identifying potential partners and establishing a meeting pipeline, is essential to achieving success on an international scale.
Patience and Persistence
Partnering is a journey that demands both patience and persistence. The partnering process is not an overnight success story. It often takes between 9 to 18 months to establish successful partnerships. Startup teams should be prepared for the ebb and flow of partner meetings while maintaining an ongoing pipeline. A dedicated staff member focused on scheduling meetings with potential partners and utilizing a Customer Relationship Management (CRM) system to track and manage the target list can help keep the process on track. LSN has just announced a Global Campaign Management product integrating the LSN partnering database with the Salesforce CRM.
Mastering the art of partnering is a critical aspect of startup success. Entrepreneurs can significantly enhance their chances of securing essential partnerships by developing a compelling storyline, understanding their target audience, expanding from regional to global, and dedicating resources to meeting engagement. Above all, patience and persistence are vital traits needed to navigate a successful global partnering campaign.
 Clinials + LSN Educational Workshop = RESI Innovator’s Pitch Challenge Success
27 Jul Maree Beare |
Interview with Maree Beare, Founder at Clinials
By Caitlin Dolegowski, Marketing Manager, LSN |
 Caitlin Dolegowski |
Maree Beare, Founder at Clinials, is a sector leader in HealthTec, FemTech and BioTech innovation. In 2021, Maree launched her second innovation, a BioTech company Clinials. Clinials is an AI-Driven clinical trial participant recruitment platform based in Brisbane, Australia, and a member of BEDA (Brisbane Economic Development Agency). Maree speaks with us about being a part of BEDA’s MedTech Accelerator cohort and her introduction to Life Science Nation followed by her eventual second-place finish in the Innovator’s Pitch Challenge at RESI Boston June earlier this summer.
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 